CN103013906A - 一种生物膜及其制备方法和应用 - Google Patents
一种生物膜及其制备方法和应用 Download PDFInfo
- Publication number
- CN103013906A CN103013906A CN2012103403109A CN201210340310A CN103013906A CN 103013906 A CN103013906 A CN 103013906A CN 2012103403109 A CN2012103403109 A CN 2012103403109A CN 201210340310 A CN201210340310 A CN 201210340310A CN 103013906 A CN103013906 A CN 103013906A
- Authority
- CN
- China
- Prior art keywords
- lymphocyte
- microbial film
- propagation
- cell
- avidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000012528 membrane Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 claims abstract description 25
- 230000004936 stimulating effect Effects 0.000 claims abstract description 17
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 43
- 230000000813 microbial effect Effects 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 33
- 210000004698 lymphocyte Anatomy 0.000 claims description 31
- 230000004913 activation Effects 0.000 claims description 23
- 238000001994 activation Methods 0.000 claims description 23
- 108090001008 Avidin Proteins 0.000 claims description 21
- 210000002950 fibroblast Anatomy 0.000 claims description 15
- 238000001556 precipitation Methods 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 15
- 230000000975 bioactive effect Effects 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 13
- 230000000638 stimulation Effects 0.000 claims description 11
- 102000002627 4-1BB Ligand Human genes 0.000 claims description 10
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 10
- 102000000588 Interleukin-2 Human genes 0.000 claims description 10
- 108010002350 Interleukin-2 Proteins 0.000 claims description 10
- 238000013016 damping Methods 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 229930003756 Vitamin B7 Natural products 0.000 claims description 6
- 230000008878 coupling Effects 0.000 claims description 6
- 238000010168 coupling process Methods 0.000 claims description 6
- 238000005859 coupling reaction Methods 0.000 claims description 6
- 238000005336 cracking Methods 0.000 claims description 6
- 230000009089 cytolysis Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000011735 vitamin B7 Substances 0.000 claims description 6
- 235000011912 vitamin B7 Nutrition 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 238000000197 pyrolysis Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 238000002525 ultrasonication Methods 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 2
- 239000006166 lysate Substances 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 abstract description 3
- 210000002751 lymph Anatomy 0.000 abstract 1
- 238000011160 research Methods 0.000 description 10
- 230000003321 amplification Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 7
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 6
- 230000003526 lymphopoietic effect Effects 0.000 description 6
- 229920001917 Ficoll Polymers 0.000 description 5
- 239000011324 bead Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 230000000527 lymphocytic effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 description 3
- 102100034924 T-lymphocyte activation antigen CD86 Human genes 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012786 cultivation procedure Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (19)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210340310.9A CN103013906B (zh) | 2012-09-14 | 2012-09-14 | 一种生物膜及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210340310.9A CN103013906B (zh) | 2012-09-14 | 2012-09-14 | 一种生物膜及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103013906A true CN103013906A (zh) | 2013-04-03 |
CN103013906B CN103013906B (zh) | 2015-04-01 |
Family
ID=47963023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210340310.9A Active CN103013906B (zh) | 2012-09-14 | 2012-09-14 | 一种生物膜及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103013906B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104922684A (zh) * | 2015-05-28 | 2015-09-23 | 杭州优玛达生物科技有限公司 | 天然来源和/或自组装技术得到的生物膜、具有生物膜性的闭合结构或细胞区室及其制备方法和应用 |
CN104997718A (zh) * | 2015-05-28 | 2015-10-28 | 杭州优玛达生物科技有限公司 | 生物膜、具有生物膜性的闭合结构或细胞区室作为化妆品或化妆品载体的应用 |
CN107794269A (zh) * | 2017-09-30 | 2018-03-13 | 成都美杰赛尔生物科技有限公司 | 促进基因编辑t细胞活化及扩增的生物膜、制法及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004092394A2 (en) * | 2003-04-08 | 2004-10-28 | The Children's Hospital Of Philadelphia | Fluid planar lipid layer-based membrane-anchored ligand system with specific binding pair members and methods of use thereof |
CN1928081A (zh) * | 2006-09-28 | 2007-03-14 | 武汉益生泉生物科技开发有限责任公司 | 一种人造生物膜及制备方法 |
CN101644711A (zh) * | 2009-09-04 | 2010-02-10 | 中国科学技术大学 | 一种可再生的生物素结合蛋白分子层及其制备方法 |
CN102128832A (zh) * | 2010-12-27 | 2011-07-20 | 江南大学 | 一种西瓜果斑病毒金标核酸试纸条及其制备和应用 |
-
2012
- 2012-09-14 CN CN201210340310.9A patent/CN103013906B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004092394A2 (en) * | 2003-04-08 | 2004-10-28 | The Children's Hospital Of Philadelphia | Fluid planar lipid layer-based membrane-anchored ligand system with specific binding pair members and methods of use thereof |
CN1928081A (zh) * | 2006-09-28 | 2007-03-14 | 武汉益生泉生物科技开发有限责任公司 | 一种人造生物膜及制备方法 |
CN101644711A (zh) * | 2009-09-04 | 2010-02-10 | 中国科学技术大学 | 一种可再生的生物素结合蛋白分子层及其制备方法 |
CN102128832A (zh) * | 2010-12-27 | 2011-07-20 | 江南大学 | 一种西瓜果斑病毒金标核酸试纸条及其制备和应用 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104922684A (zh) * | 2015-05-28 | 2015-09-23 | 杭州优玛达生物科技有限公司 | 天然来源和/或自组装技术得到的生物膜、具有生物膜性的闭合结构或细胞区室及其制备方法和应用 |
CN104997718A (zh) * | 2015-05-28 | 2015-10-28 | 杭州优玛达生物科技有限公司 | 生物膜、具有生物膜性的闭合结构或细胞区室作为化妆品或化妆品载体的应用 |
CN107794269A (zh) * | 2017-09-30 | 2018-03-13 | 成都美杰赛尔生物科技有限公司 | 促进基因编辑t细胞活化及扩增的生物膜、制法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103013906B (zh) | 2015-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102268405B (zh) | 自体nk细胞体外活化扩增培养的方法及其专用培养基 | |
CN105112370B (zh) | 一种体外刺激外周血γδT细胞高效增殖的方法及其应用 | |
CN103849599B (zh) | 一种高效扩增自体nk细胞的培养基及培养方法 | |
CN105087487B (zh) | 一种高效扩增cik的方法 | |
CN102321581B (zh) | 腹水肿瘤细胞致敏dc-cik的制备方法 | |
CN105754941A (zh) | 一种外周血nk细胞的体外诱导扩增培养方法 | |
CN105907719A (zh) | Anti ROBO1 CAR-T细胞及其制备和应用 | |
CN102676453A (zh) | 一种nk和/或nkt细胞的培养方法 | |
Glienke et al. | GMP-compliant manufacturing of TRUCKs: CAR T cells targeting GD2 and releasing inducible IL-18 | |
CN104357394A (zh) | 一种自体外周血淋巴细胞dc-cik的培养方法 | |
CN105316362A (zh) | 一种Dual-RMCE介导的TCR基因置换系统及其方法 | |
CN105378071A (zh) | 用于产生稳定转染细胞的方法和组合物 | |
CN109234232A (zh) | 兔外周血b细胞的培养体系及培养方法、抗体的制备方法和应用 | |
CN103013906B (zh) | 一种生物膜及其制备方法和应用 | |
CN109957543A (zh) | 利用脐带血大量扩增脐血nk细胞的方法 | |
CN106085957B (zh) | 一种微载体三维扩增并激活自然杀伤细胞的方法 | |
CN104762261A (zh) | 一种肿瘤浸润淋巴细胞的分离方法 | |
CN107794269A (zh) | 促进基因编辑t细胞活化及扩增的生物膜、制法及应用 | |
Elsner et al. | 51Cr-release to monitor NK cell cytotoxicity | |
CN100369934C (zh) | 抗人4-1bbl单克隆抗体制备及其应用 | |
CN106119193B (zh) | 一种兼有nk细胞特质的抗原特异性t细胞的制备方法 | |
CN105925526A (zh) | 一种增强cik细胞活性的方法与cik细胞及其制备方法和应用 | |
CN106479973B (zh) | 一种体外iak免疫细胞培养方法 | |
Qiu et al. | Improving the ex vivo expansion of human tumor-reactive CD8+ T cells by targeting toll-like receptors | |
Heger et al. | XCR1 expression distinguishes human conventional dendritic cell type 1 with full effector functions from their immediate precursors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171023 Address after: 215123 room D101-104, No. 99, Suzhou Road, Suzhou Industrial Park, Jiangsu, China Patentee after: PERSONGEN BIOTHERAPEUTICS (SUZHOU) Co.,Ltd. Address before: 215123 B2 building, No. 99 benevolence Road, Jiangsu, Suzhou Co-patentee before: Huang Gangxiong Patentee before: PERSONGEN BIOTHERAPEUTICS (SUZHOU) Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230526 Address after: Building B2, National Health Big Data Industrial Park, No. 99 Kongquetai Road, High tech Zone, Hefei City, Anhui Province, 230000 Patentee after: BOSHENG JIANKE CELL TECHNOLOGY CO.,LTD. Address before: Room d101-104, 99 Ren'ai Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123 Patentee before: PERSONGEN BIOTHERAPEUTICS (SUZHOU) Co.,Ltd. |
|
TR01 | Transfer of patent right |